OncoSec Medical IncのEV/EBIT
OncoSec Medical IncのEV/EBITは何ですか。
OncoSec Medical IncのEV/EBITはN/Aです。
EV/EBITの定義は何ですか。
Enterprise value to earnings before interest and taxes (EV/EBIT) is a financial ratio used to measure if a stock is priced appropriately to similar stocks and the market. It is similar to the P/E ratio.
ttm (trailing twelve months)
The EV/EBIT ratio addresses some of the shortcomings of the P/E ratio. Instead of taking market capitalization, the ratio uses enterprise value, as it takes into account the true value of the company. Enterprise value includes both equity and debt. It is calculated as:
Enterprise value = market cap + total debt – cash and cash equivalents
The EV/EBIT ratio is useful in comparing peers within the wider market. A high EV/EBIT ratio indicates that a company’s stock is overvalued. On the opposite, a low EV/EBIT ratio indicates that a company’s stock is undervalued. The lower the ratio, the more financially stable a company should be. However, investors and analyst should use other ratios and information to get a full picture of a company’s financial state and actual value.
NASDAQのセクタHealth CareにおけるEV/EBITの企業と比べるOncoSec Medical Inc
OncoSec Medical Incは何をしますか。
oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar
OncoSec Medical Incと類似のev/ebit
- Phoenix Global Resources PlcのEV/EBITはN/Aです。
- OssDsign AB (publ)のEV/EBITはN/Aです。
- Canadian General InvestmentsのEV/EBITはN/Aです。
- Omnia Metals LtdのEV/EBITはN/Aです。
- Netgear IncのEV/EBITはN/Aです。
- VroomのEV/EBITはN/Aです。
- OncoSec Medical IncのEV/EBITはN/Aです。
- Hemogenyx Pharmaceuticals PlcのEV/EBITはN/Aです。
- Akari Therapeutics PlcのEV/EBITはN/Aです。
- Youngevity International IncのEV/EBITはN/Aです。
- Sigma Labs IncのEV/EBITはN/Aです。
- GOLO MobileのEV/EBITはN/Aです。
- NeuroOne Medical TechnologiesのEV/EBITはN/Aです。